GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » Piotroski F-Score

Hangzhou Tigermed Consulting Co (SZSE:300347) Piotroski F-Score : 3 (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hangzhou Tigermed Consulting Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Piotroski F-Score or its related term are showing as below:

SZSE:300347' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 3

During the past 13 years, the highest Piotroski F-Score of Hangzhou Tigermed Consulting Co was 6. The lowest was 3. And the median was 5.


Hangzhou Tigermed Consulting Co Piotroski F-Score Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Piotroski F-Score Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 4.00 3.00 3.00

Hangzhou Tigermed Consulting Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

Competitive Comparison of Hangzhou Tigermed Consulting Co's Piotroski F-Score

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 568.455 + 819.882 + 491.267 + 145.246 = ¥2,025 Mil.
Cash Flow from Operations was 28.508 + 346.533 + 297.603 + 477.793 = ¥1,150 Mil.
Revenue was 1804.571 + 1906.279 + 1939.628 + 1733.562 = ¥7,384 Mil.
Gross Profit was 715.522 + 765.564 + 798.471 + 568.971 = ¥2,849 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(27446.511 + 28172.128 + 29666.676 + 30072.449 + 29680.742) / 5 = ¥29007.7012 Mil.
Total Assets at the begining of this year (Dec22) was ¥27,447 Mil.
Long-Term Debt & Capital Lease Obligation was ¥857 Mil.
Total Current Assets was ¥11,344 Mil.
Total Current Liabilities was ¥4,139 Mil.
Net Income was 518.417 + 673.587 + 412.655 + 401.893 = ¥2,007 Mil.

Revenue was 1817.859 + 1776.35 + 1811.81 + 1679.453 = ¥7,085 Mil.
Gross Profit was 705.848 + 721.028 + 741.698 + 639.89 = ¥2,808 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(23741.172 + 24803.252 + 25703.18 + 27140.007 + 27446.511) / 5 = ¥25766.8244 Mil.
Total Assets at the begining of last year (Dec21) was ¥23,741 Mil.
Long-Term Debt & Capital Lease Obligation was ¥734 Mil.
Total Current Assets was ¥11,107 Mil.
Total Current Liabilities was ¥3,730 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hangzhou Tigermed Consulting Co's current Net Income (TTM) was 2,025. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hangzhou Tigermed Consulting Co's current Cash Flow from Operations (TTM) was 1,150. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=2024.85/27446.511
=0.0737744

ROA (Last Year)=Net Income/Total Assets (Dec21)
=2006.552/23741.172
=0.08451782

Hangzhou Tigermed Consulting Co's return on assets of this year was 0.0737744. Hangzhou Tigermed Consulting Co's return on assets of last year was 0.08451782. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hangzhou Tigermed Consulting Co's current Net Income (TTM) was 2,025. Hangzhou Tigermed Consulting Co's current Cash Flow from Operations (TTM) was 1,150. ==> 1,150 <= 2,025 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=857.332/29007.7012
=0.02955532

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=733.617/25766.8244
=0.02847138

Hangzhou Tigermed Consulting Co's gearing of this year was 0.02955532. Hangzhou Tigermed Consulting Co's gearing of last year was 0.02847138. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=11344.141/4138.736
=2.74096753

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=11107.248/3729.567
=2.9781602

Hangzhou Tigermed Consulting Co's current ratio of this year was 2.74096753. Hangzhou Tigermed Consulting Co's current ratio of last year was 2.9781602. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hangzhou Tigermed Consulting Co's number of shares in issue this year was 862.751. Hangzhou Tigermed Consulting Co's number of shares in issue last year was 871.413. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2848.528/7384.04
=0.38576822

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2808.464/7085.472
=0.39636936

Hangzhou Tigermed Consulting Co's gross margin of this year was 0.38576822. Hangzhou Tigermed Consulting Co's gross margin of last year was 0.39636936. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=7384.04/27446.511
=0.26903383

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=7085.472/23741.172
=0.2984466

Hangzhou Tigermed Consulting Co's asset turnover of this year was 0.26903383. Hangzhou Tigermed Consulting Co's asset turnover of last year was 0.2984466. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hangzhou Tigermed Consulting Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Hangzhou Tigermed Consulting Co  (SZSE:300347) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hangzhou Tigermed Consulting Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines